Opinion|Videos|January 13, 2025
Discussing Real-World Ruxolitinib and Corticosteroid Treatment Patterns in Patients with cGVHD
Author(s)Sergio A. Giralt, MD
Sergio A. Giralt, MD, discusses how he selects patients with chronic graft-vs-host disease (cGVHD) for treatment with ruxolitinib, often in combination with corticosteroids, and reviews the study design and methods of recent research on ruxolitinib in cGVHD management, highlighting key efficacy and safety results and how these findings align with his clinical practice.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Which patients with chronic graft-vs-host disease (cGVHD) do you treat with ruxolitinib in your clinical practice?
- Do you use corticosteroids concurrently with ruxolitinib?
- What were this abstract’s study design and methods, and why was it important to investigate for cGVHD management?
- What were the key efficacy and safety results seen in this abstract?
- Do these results align with what you see in your clinical practice?
Advertisement
Related to this article
Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.
A 20-year Danish registry study found higher antidepressant and anxiolytic use among women with endometriosis, both before and after diagnosis.
AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
GRADE meta-analysis: hepatitis A vaccine blocks 96% in pre-exposure vaccination; outbreak response uses millions of doses, but post-exposure prophylaxis evidence is weak.
Alcohol abuse was the strongest post-trauma psychiatric predictor of cardiovascular events, with mood disorders more prominent among women.
Individuals with or at risk for arrhythmogenic cardiomyopathy had no added risk of ventricular arrhythmia from strength training, unlike endurance exercise.
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
2
Twice-Yearly CD19 Therapy Targets MG Root Cause: Richard Nowak, MD, MS
3
GLP-1 Receptor Agonists Cut Ascites, Mortality in MASH
4
Hepatitis A Vaccine Prevents 96% of Infections Given Before Exposure
5